Alnylam Pharmaceuticals (ALNY) – Analysts’ Recent Ratings Updates


Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:

5/10/2018 – Alnylam Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alnylam posted wider than expected loss and missed revenue estimates in the first quarter of 2018. The company reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.” 5/8/2018 – Alnylam Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $103.00 price target on the stock. According to Zacks, “Alnylam posted wider than expected loss and missed revenue estimates in the first quarter of 2018. The company reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.” 5/7/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at Morgan Stanley to $118.00. They now have an “equal weight” rating on the stock. 5/4/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $160.00 to $134.00. They now have an “outperform” rating on the stock. 5/4/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $107.00 to $95.00. They now have a “hold” rating on the stock. 5/2/2018 – Alnylam Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating. 4/17/2018 – Alnylam Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Alnylam reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and an action date of Aug 11, 2018 as set by the FDA. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. Stiff competition remains a threat as well. Estimates have remained stable ahead of the Q1 earnings results.” 4/4/2018 – Alnylam Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 4/2/2018 – Alnylam Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating. 4/2/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $200.00 price target on the stock. 4/2/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. 3/28/2018 – Alnylam Pharmaceuticals is now covered by analysts at Evercore ISI. They set a “line” rating and a $143.00 price target on the stock. 3/28/2018 – Alnylam Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating. 3/26/2018 – Alnylam Pharmaceuticals had its price target raised by analysts at JMP Securities from $169.00 to $207.00. They now have an “outperform” rating on the stock.


ALNY traded up $0.72 during midday trading on Friday, reaching $102.36. The company had a trading volume of 493,260 shares, compared to its average volume of 1,000,817. The company has a quick ratio of 14.61, a current ratio of 14.61 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of -18.88 and a beta of 2.73. Alnylam Pharmaceuticals, Inc. has a 1 year low of $100.89 and a 1 year high of $102.50.

Get Alnylam Pharmaceuticals Inc alerts:

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.


In other news, SVP Laurie Keating sold 20,000 shares of the company’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $145.00, for a total value of $2,900,000.00. Following the completion of the transaction, the senior vice president now owns 24,500 shares of the company’s stock, valued at $3,552,500. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Akshay Vaishnaw sold 88,554 shares of the company’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $143.10, for a total value of $12,672,077.40. Following the completion of the transaction, the insider now directly owns 55,856 shares of the company’s stock, valued at approximately $7,992,993.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 198,620 shares of company stock valued at $28,404,143. Corporate insiders own 4.30% of the company’s stock.


Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Guggenheim Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 1.1% in the first quarter. Guggenheim Capital LLC now owns 53,084 shares of the biopharmaceutical company’s stock worth $6,323,000 after acquiring an additional 600 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock worth $21,156,000 after acquiring an additional 629 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 10.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock worth $915,000 after acquiring an additional 700 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 27.0% in the first quarter. Daiwa Securities Group Inc. now owns 3,428 shares of the biopharmaceutical company’s stock worth $408,000 after acquiring an additional 728 shares during the period. Finally, Public Employees Retirement Association of Colorado boosted its stake in shares of Alnylam Pharmaceuticals by 4.4% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 17,321 shares of the biopharmaceutical company’s stock worth $2,201,000 after acquiring an additional 736 shares during the period. 92.14% of the stock is owned by hedge funds and other institutional investors.


Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).